Felix D. Rozenberg

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos‐Cuentas, Martín Casapía, Raúl Chuquiyauri et al. · The Lancet Infectious Diseases · 2018 · 144 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital

Angela Gomez‐Simmonds, Medini K. Annavajhala, Thomas H. McConville et al. · Journal of Antimicrobial Chemotherapy · 2020 · 101 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

CrrB Positively Regulates High-Level Polymyxin Resistance and Virulence in Klebsiella pneumoniae

Thomas H. McConville, Medini K. Annavajhala, Marla J. Giddins et al. · Cell Reports · 2020 · 57 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048

James McCarthy, Cristina Donini, Stephan Chalon et al. · Clinical Infectious Diseases · 2020 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Mapping the genomic landscape of multidrug resistance in <i>Plasmodium falciparum</i> and its impact on parasite fitness

Sachel Mok, Tomas Yeo, Davin Hong et al. · Science Advances · 2023 · 28 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14